Loading organizations...
Loading organizations...
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 2, 2026 | ZhiTai Biotech | $72.8M Series C | OrbiMed | BlueRun Ventures, Haoyue Capital, Huagai Capital, Qiming Venture Partners, Wuyuan Capital, Xingze Capital |
| Jan 11, 2021 | NuProbe | $42.0M Other Equity | Wen Chen | Hongshan Capital Group (Sequoia Capital China), Juming Capital, Panlin Capital, Ruomu Capital, Serica Partners, Tuobang Capital |